Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Capecitabine.

M Dooley1, K L Goa

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|August 10, 1999
PubMed
Summary
This summary is machine-generated.

Capecitabine offers a treatment option for refractory breast cancer, showing a 20% response rate and a median survival of 384 days. Further trials indicate improved outcomes compared to traditional chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Challenges of Tacrolimus for Maintenance Immunosuppression Post-Lung Transplantation.

Transplantation proceedings·2017
Same author

Morphological appearance of uterine cavity on ultrasound prior to development of intrauterine adhesions.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2017
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice.

Internal medicine journal·2016
Same author

The impact of the introduction of an acute sedation practice guideline.

Acta neuropsychiatrica·2016
Same author

Sport, exercise and the menstrual cycle: where is the research?

British journal of sports medicine·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Capecitabine is an oral fluoropyrimidine carbamate used for advanced breast cancer.
  • It is converted to 5-fluorouracil (5-FU) in a three-step process, with preferential activation in tumor tissue.

Purpose of the Study:

  • To evaluate the efficacy and safety of capecitabine in patients with paclitaxel- or anthracycline-refractory breast cancer.
  • To compare oral capecitabine with intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) in previously untreated breast cancer patients.

Main Methods:

  • Patients received oral capecitabine at 2510 mg/m2/day for 2 weeks followed by 1 week off.
  • Tumor response, disease progression, duration of response, time to progression, and survival were assessed.
  • Adverse events were monitored.

Related Experiment Videos

Main Results:

  • In paclitaxel-refractory breast cancer, objective tumor response rate was 20%, with 40% stable disease and 34% progression.
  • Median duration of response was 241 days; median time to progression was 93 days; median survival was 384 days.
  • Previously untreated patients showed higher response rates and longer progression-free survival with capecitabine compared to intravenous CMF.

Conclusions:

  • Capecitabine demonstrates clinical activity in refractory breast cancer.
  • Oral capecitabine presents a potentially more effective and convenient alternative to intravenous CMF for certain breast cancer indications.
  • Common adverse events include gastrointestinal and hematological toxicities, hand-and-foot syndrome, fatigue, and anorexia.